Managers / Q1 2022 · view latest →
Lion Point Capital, LP
CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200
Summary
Lion Point Capital, LP reported $431M in U.S.-listed holdings across 35 positions for Q1 2022.
Its largest position, SWCHF, represents 8.4% of the portfolio.
Compared with Q4 2021, the fund opened 6 new positions and exited 5.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 74.6% · $321M
- ETP · 19.5% · $84M
- Other · 5.3% · $23M
- US DOMESTIC · 0.6% · $3M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| WTWISDOMTREE INVTS INC | NEW | +4.52M | 4.52M | +$27M | $27M |
| IBMINTERNATIONAL BUSINESS MACHS | NEW | +142.0K | 142.0K | +$18M | $18M |
| OPTUALTICE USA INC | NEW | +900.0K | 900.0K | +$11M | $11M |
| PDC ENERGY INC | NEW | +130.4K | 130.4K | +$9M | $9M |
| MISTMILESTONE PHARMACEUTICALS IN | NEW | +683.6K | 683.6K | +$4M | $4M |
| IMARA INC | NEW | +834.8K | 834.8K | +$2M | $2M |
| KINIKSA PHARMACEUTICALS LTD | ADDED | +425.0K | 480.0K | +$4M | $5M |
| XOPSPDR SER TR | ADDED | +500.0K | 625.0K | +$72M | $84M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | SWCHFSIERRA WIRELESS INChistory → | COM | 8.42% | $36M | 2.01M |
| 2 | MARINUS PHARMACEUTICALS INC | COM NEW | 7.87% | $34M | 3.63M |
| 3 | WTWISDOMTREE INVTS INChistory → | COM | 6.16% | $27M | 4.52M |
| 4 | CTI BIOPHARMA CORP | COM | 5.95% | $26M | 5.49M |
| 5 | CHRDOASIS PETROLEUM INChistory → | COM NEW | 5.94% | $26M | 175.0K |
| 6 | ARCONIC CORPORATION | COM | 4.98% | $21M | 837.4K |
| 7 | TRICIDA INC | COM | 3.48% | $15M | 1.83M |
| 8 | IVERIC BIO INC | COM | 2.76% | $12M | 706.2K |
| 9 | BURGERFI INTERNATIONAL INC | COM | 2.66% | $11M | 2.75M |
| 10 | OPTUALTICE USA INChistory → | CL A | 2.61% | $11M | 900.0K |
| 11 | DURECT CORP | COM | 2.41% | $10M | 15.49M |
| 12 | CIVICIVITAS RESOURCES INChistory → | COM NEW | 2.29% | $10M | 165.0K |
| 13 | PDC ENERGY INC | COM | 2.20% | $9M | 130.4K |
| 14 | RENEW ENERGY GLOBAL PLC | CL A SHS | 1.91% | $8M | 1.00M |
| 15 | ENERPLUS CORP | COM | 1.69% | $7M | 575.0K |
| 16 | BATLBATTALION OIL CORPhistory → | COM | 1.52% | $7M | 352.9K |
| 17 | KINIKSA PHARMACEUTICALS LTD | COM CL A | 1.11% | $5M | 480.0K |
| 18 | MISTMILESTONE PHARMACEUTICALS INhistory → | COM | 1.02% | $4M | 683.6K |
| 19 | VASCULAR BIOGENICS LTD | COM | 1.02% | $4M | 2.59M |
| 20 | SERES THERAPEUTICS INC | COM | 0.80% | $3M | 481.8K |
| 21 | IQIYI INC | NOTE 4.000%12/1 | 0.64% | $3M | 4.00M |
| 22 | IMARA INC | COM | 0.36% | $2M | 834.8K |
| 23 | INNOVIZ TECHNOLOGIES LTD | SHS | 0.34% | $1M | 400.0K |
| 24 | AEGLEA BIOTHERAPEUTICS INC | COM | 0.16% | $690,000 | 300.0K |
| 25 | ORIGIN MATERIALS INC | COM | 0.15% | $658,000 | 100.0K |
| 26 | IBMINTERNATIONAL BUSINESS MACHS | COM | 0.15% | $650,000 | 5.0K |
| 27 | LUMOS PHARMA INC | COM | 0.11% | $481,000 | 51.2K |
| 28 | SDIGSTRONGHOLD DIGITAL MINING IN | CLASS A COM | 0.03% | $117,000 | 20.0K |
| 29 | AAALCOA CORP | COM | 0.02% | $90,000 | 1.0K |
| 30 | COMSCORE INC | COM | 0.00% | $2,000 | 1.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $17M | 35 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $19M | 39 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $18M | 27 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $15M | 19 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $16M | 21 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $19M | 19 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $45M | 25 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $55M | 27 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $179M | 32 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $200M | 30 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $224M | 31 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $221M | 30 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $243M | 31 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $703M | 32 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $454M | 41 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $878M | 40 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $431M | 35 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $373M | 33 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $533M | 38 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $579M | 34 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $550M | 30 | May 19, 2021 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2020 | $519M | 24 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $456M | 24 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $412M | 24 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $379M | 25 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $1.1B | 26 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $897M | 26 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $1.0B | 24 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $1.1B | 24 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $636M | 35 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.